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160Gy to the PTV (GTV + 2mm) and Bard Quicklink system is 
used to implant I125 radioactive seeds. Multi-modal manual 
rigid and non-rigid transformations between MR and CT scans 
were performed on the first 9 patients with three software 
solutions: the treatment planning system Variseed, a 
research platform 3D Slicer and a commercial solution 
Mirada. MR onto CT registrations were approved by an expert 
uro-radiologist and quantitative evaluations of the 
registrations were performed by calculating the means of 
vectors displacement marked on four relevant points of 
interest detected on the I125 seeds. For the dosimetry, an 
assessment of the impact of these readjustments on the 
initial dose matrix was also performed in Mirada by applying 
the deformation to the initial contours and injecting the 
initial dose matrix. 
 
Results: For the first 9 patients, evaluation of registration 
gives means of vectors displacement of 1.52mm [0.36-2.6] 
with Variseed, 0.62mm [0.26-1.29] with 3D Slicer and 
0.42mm [0.24-0.81] with Mirada. Examples of fusions are 
illustrated in Figure1. Concerning the dosimetric data and 
considering the most relevant criteria from the initial 
outline, the D90%(Gy) to the prostate and respectively for 
the target has a mean difference of +0.68Gy and -12Gy. The 
D30%(Gy) and the D10%(Gy) to the urethra respectively have 
a mean difference of -0.99 and -5.58Gy. Lastly, D1cc(Gy) to 
the rectum has a mean difference of +4,37Gy. 
 
 
 
Conclusion: Target volume definition remains a crucial step 
for focal brachytherapy as only confirmed tumor biopsy sub-
volumes of the prostate are treated. Registration procedures 
tested in our institute confirmed the need to implement 
precise rigid and non-rigid fusion of image to delineate 
relevant target volumes on different modalities. In addition, 
dosimetry evaluation on the registrations showed the impact 
of the deformations in high dose gradients. 
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Purpose or Objective: The High-dose-rate brachytherapy as 
monotherapy in one fraction, is a treatment option in 
patients with low-risk prostate cancer and can be used as an 
alternative to the low-dose-rate brachytherapy.Compared to 
the low-dose-rate, the HDR as monotherapy has not proven 
long-term results with regard to disease control. It is not 
known what dose of treatment should be used to increase the 
biochemical control, survival control disease and reduce 
unaffordable toxic effects. 
 
Material and Methods: Results on patients treated with high-
dose-rate brachytherapy as monotherapy are presented 
below. 
Sample: A series of 75 patients between 2008 and 2013 
treated with high-dose-rate brachytherapy (HDR) single dose 
of 19 Gy (62) and 20.5 Gy (13) were selected. 
A technique of guided-ultrasound brachytherapy and 
dynamic-calculated intraoperative dose was used. 
 
Results: The results show an overall survival of 91.3% of 
patients, with survival free of disease of 97% and a 
biochemical control of 72.5%. 
Patients toxicity: Acute urinary toxicity: 53.8% (grade 2). 
Chronic urinary toxicity: 49.2% (grade 2). Acute 
gastrointestinal toxicity: 86.2% (grade 1). Chronic 
gastrointestinal toxicity: 89% (grade 1).Acute urinary 
retention rate of 2.9%. 
 
Conclusion: HDR prostate brachytherapy as monotherapy in 
one single fraction of 19 Gy does not provided adequate 
biochemical control and survival free disease rates. It is 
necessary more studies to establish what would be the most 
appropiate dose to obtain higher rates of disease control 
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Purpose or Objective: Evaluate the relationship between 
RTOG G2-G3 urinary morbidity after prostate brachytherapy 
and urethral doses at the end of real-time dosimetry 
planning. 
 
Material and Methods: From November 2007 to December 
2010, 204 prostate cancer patients underwent monotherapy 
I-125 seeds brachytherapy in our institution. Real-time US 
guided dosimetry planning was performed with Variseed 7.0 
or 8.0. Of the 204 patients, 11 (5.4%) developed an acute 
urinary retention and required a urinary catheter from 2 
weeks to 7 months (G2 morbidity), and 7 patients (3.4%) 
required a transurethral resection of the prostate (G3 
morbidity).  
In a retrospective study, detailed urethral dosimetry was 
evaluated at the end of the real-time implant. Assessed 
values included maximum dose, V80, V100, V150 and D90 for 
both overall urethra and segmented urethra (as base, 
midgland and apex urethra). 1.5-mm and 2.5-mm urethral 
expansions were also reviewed for all dosimetry parameters. 
To check if dose homogeneity around urethral regions was 
related to morbidity, subtraction of expanded minus non-
expanded urethral dosimetry parameters was also performed. 
In total, 111 parameters were reviewed.  
T-Student test and U Mann-Whitney test were used to 
compare differences between patients free of urinary 
morbidity from those presenting G2 and G3 morbidity. p 
<0.05 was considered significant. 
 
Results: No correlation was found between non-expanded 
urethra doses and urinary morbidity. 
Best result (p=0.005) for distinguishing free-morbidity cohort 
from G2-G3 morbidity-cohort was obtained for subtraction of 
the maximum dose of the non-expanded minus 2.5-mm-
expanded overall urethra.  
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Diagnostic capability was determined by calculating the area 
under the curve (AUC) in the receiver operating 
characteristic (ROC) curves. This parameter had an AUC value 
of 0.786. It was predictive of G2-G3 complications with 71.4% 
specificity and 72.2% sensibility for a dose difference 
threshold of 48 Gy. 
 
Conclusion: A non-homogenous dose region around urethra at 
the end of the real-time implant is a risk factor for 
development of urethral morbidity.  
Several studies have found dosimetry correlations between 
CT post-plan and urinary morbidity. This study focuses on US 
real-time dosimetry parameters. It allows us to consider new 
constraints and dosimetry alerts during treatment planning.  
A prospective study is under consideration, where a new 
constraint of a 40-50 Gy maximum dose difference around a 
2.5-mm expansion of the urethra will be implemented if 
feasible. 
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Purpose or Objective: The PSA level after definitive 
treatment using radiotherapy decreases but still remains 
detectable. The aim of this study is to analyze clinical and 
dosimetric factors which influence the PSA level in the blood 
serum of patients with prostate cancer after HDR (High Dose 
Rate) brachytherapy. 
 
Material and Methods: 53 patients after HDR brachytherapy 
were qualified to the study from June 2008 to December 
2010. The patients were from T1c to T2c , iPSA from 1.5 to 
19.6 ng / ml with prostate adenocarcinoma (Gleason Scale < 
7) and belonged to the low and intermediate risk of 
recurrence. 20 patients had androgen deprivation therapy. 
Patients were treated with HDR brachytherapy 3 x 15 Gy or 3 
x 10.5 Gy. Median follow-up was 3 years. The PSA Bounce 
threshold was >0.2 ng/ml and the biochemical failure 
definition was nadir PSA +2.0 ng/ml. The influences of 
clinical and dosimetric parameters were assessed . Statistical 
analysis was performed assuming significance level p < 0.05. 
 
Results: PSA Bounce occurred in 22% after average 10.7 
months. The time to PSA increase in BF group after 
brachytherapy HDR was 36 months. It was observed that 
patients with PSA nadir below 0.1 ng/ml were more likely to 
have normal follow-up than PSA Bounce, biochemical failure 
(BF), clinical failure (CF). The amplitude of the PSA increases 
were significantly different between subgroups. The further 
analysis demonstrated only a significant difference between 
the subgroup HDR_Bounce (median 0.7 ng/ml) and HDR_BF 
(median 2.6 ng/ml). The time to PSA increase was 
significantly different between the subgroups of the group 
HDR. It applies to patients with PSA Bounce (median 10.5 
months) and biochemical failure (median 36 months). The 
analysis of others dosimetric and clinical factors (including 
hormonotherapy) didn’t show any significant effect on the 
studied HDR subgroups. 
 
Conclusion: The percentage of patients who had a PSA 
Bounce was 22%. Predisposing factors for PSA Bounce after 
HDR brachytherapy were nadir PSA (median> 0.1 ng / ml) and 
time to PSA increase (median <12 months). There was no 
influence of other analyzed clinical, dosimetric factors and 
use of hormone therapy to occurrence of the PSA Bounce. 
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Purpose or Objective: To evaluate evolution and average 
time to IPSS (International Prostate Symptom Score) 
recovery, in patients who have been submitted to I-125 
prostate brachytherapy (Low dose rate brachytherapy). 
 
Material and Methods: Between March 2011 and December 
2013 we performed 66 prostate brachytherapy in patients 
with low / intermediate risk prostate cancer. 4 patients also 
received external radiotherapy. 14 patients received previous 
hormone therapy. A 145 Gy dose was prescribed if exclusive 
brachytherapy was given and 108 Gy if combined with 
external radiotherapy. All patients were treated with 
Quicklink Delivery System® (BARD) and real-time 
planification. Of the 66 treated patients 5 did not have initial 
IPSS, 13 did not have complete follow up, and the 48 
remaining have a suitable follow up. The variables that have 
been evaluated were: Prostate volume, Qmax, number of 
implanted seeds, number of needles and Urethra´s D1; “p 
value” was obtained from Mann-Whitney test. The prostate 
average volume was 33.73 cc, Qmax: 18.7 ml/sec, number of 
seeds: 60.2, number of needles: 16.1 and urethra`s D1: 138% 
to the prescribed dose. 
 
Results: With an average follow up of 27 months, 41 of 48 
patients (85.4%) recovered their IPSS, with an average 
recovery time of 9 months. 7 patients (15%) showed 
progressive worsening without recovery, and 3 (4.5%) of them 
developed acute urinary retention (AUR) one month after the 
implant. In a multivariate analysis the main factor that 
influenced AUR was the prostate volume, with p= 0.0583, (in 
these 3 patients prostate volume average was 42.47 cc, 
higher than the average non AUR) and other factors that 
seem to influence were IPSS and Qmax values, without 
statistical significance ("p" value) (In these patients Qmax 
average was 7.63 and IPSS average was 9.33, worse than non 
AUR). 
 
Conclusion: 85% of patients with complete follow-up, 
recovered its basal IPSS. The average time to recovery was 9 
months, and the incidence of acute urinary retention was 
lower than 4.5%.  
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